Investor Overview

Corporate Profile

Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-100 is an oral alpha-4-beta-7 integrin antagonist peptide  that was being developed for inflammatory bowel diseases (IBD). ... Read more

Stock Quote

PTGX (Common Stock)
$8.77 + 0.28 (3.30%)
Exchange :NASDAQ
Volume :64,978
Today's Open$8.39
Previous Close$8.49
Data as of November 16, 2018 4:00 p.m. ET
Refresh quote

Stock Chart

Stock chart for: PTGX.O.  Currently trading at $8.77 with a 52 week high of $23.97 and a 52 week low of $5.50.

Recent Press Releases

November 07, 2018

Protagonist Therapeutics to Present at the Stifel 2018 Healthcare Conference Wednesday, Nov. 14 read more

November 06, 2018

Protagonist Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update read more

November 06, 2018

Protagonist Therapeutics Announces Completion of Phase 1 Clinical Trial of Oral IL-23 Receptor Antagonist PTG-200 read more

Upcoming Events

There are currently no events scheduled.


Download Documentation Investor Presentation
Data provided by Nasdaq. Minimum 15 minutes delayed.